Standing out in a competitive life sciences market is essential for attracting investors, partners, talent and media attention.

We support life sciences companies to define their corporate story, sharpen their positioning and build communications programmes that support business objectives. Through messaging workshops, we identify what makes your company distinctive, who needs to hear your story and the most effective channels to reach them.

From corporate identity and website development to executive visibility and conference speaking opportunities, we help ensure every communication activity reinforces a clear and consistent narrative. Our strategic counsel aligns corporate, investor, partnering and media communications to maximise impact and support long-term reputation building.

Services

  • Strategic communications counsel
  • Corporate positioning & message development
  • Corporate branding & identity
  • Website strategy & development
  • Corporate materials & presentations
  • Executive visibility & thought leadership
  • Speaker platforms & industry engagement
  • Sponsorship & partnership opportunities
  • Media relations
  • Crisis & issues management
  • Media & presentation training
  • Copywriting & speech writing

Case Studies

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

Igyxos: Raising the profile of a novel infertility treatment

Positioning Igyxos as a thought leader in monoclonal-based fertility innovation and elevating its profile ahead of clinical and investor milestones.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Positioning Concept Life Sciences as a partner of choice from concept to clinic

Positioning a leading CRO as a partner of choice through strategic messaging, media outreach and high-impact trade coverage.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

Igyxos: Raising the profile of a novel infertility treatment

Positioning Igyxos as a thought leader in monoclonal-based fertility innovation and elevating its profile ahead of clinical and investor milestones.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Positioning Concept Life Sciences as a partner of choice from concept to clinic

Positioning a leading CRO as a partner of choice through strategic messaging, media outreach and high-impact trade coverage.